 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
|
|
|
|
Phase IV
|
|
|
|
U2963n
NCT00097565
|
|
| |
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
|
|
|
|
Phase III, Phase II
|
|
|
|
GC P#02.01.001
NCT00469729
|
|
| |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
|
|
|
|
Phase III, Phase II
|
|
|
|
RPCI-I-72806
I 72806, NCT00536601
|
|
| |
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
|
|
|
Phase III, Phase II
|
|
|
|
0705-20 IUCRO-0196
NCT00594308
|
|
| |
Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies
|
|
|
|
Phase III, Phase II
|
|
|
|
F080429003
UAB-0775, NCT00714259
|
|
| |
Pixantrone or Other Chemotherapy Drugs in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
|
|
|
|
Phase III
|
|
|
|
UCLA-0406049-01
CTI-PIX301, NCT00101049
|
|
| |
Mobilization of Stem Cells with AMD3100 in Non-Hodgkin’s Lymphoma Patients
|
|
|
|
Phase III
|
|
|
|
AMD3100-3101
NCT00103610
|
|
| |
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
|
|
|
|
Phase III
|
|
|
|
CALGB-50303
CALGB-50303, ECOG-50303, NCI-05-C-0252, NCT00118209
|
|
| |
PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
|
|
|
|
Phase III
|
|
|
|
9823
H6Q-MC-JCBJ, PRELUDE, NCT00332202
|
|
| |
Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)
|
|
|
|
Phase III
|
|
|
|
384
BMT CTN 0401, U01 HL069294-05, NCT00329030
|
|
